Effect of Fuzheng Quxie Formula on progression⁃free survival in lung cancer patients

ZHANG Bo; ZHOU Yiyang; ZHANG Minfeng; XU Lili; LUO Yingbin; WU Jianchun; WANG Weiyu; TIAN Jianhui; LI Yan

doi:10.16305/j.1007-1334.2024.2404061

您当前的位置：

首页 >

文章列表页 >

Effect of Fuzheng Quxie Formula on progression⁃free survival in lung cancer patients

更新时间：2024-12-23

- Effect of Fuzheng Quxie Formula on progression⁃free survival in lung cancer patients
- Shanghai Journal of Traditional Chinese Medicine Vol. 58, Issue 12, Pages: 114-118(2024)
- 作者机构：
  
  上海中医药大学附属市中医医院（上海 200071）
- 作者简介：
- 基金信息：
- DOI：10.16305/j.1007-1334.2024.2404061
  CLC：
- Published：10 December 2024，
  
  Received：14 April 2024，
- 稿件说明：
移动端阅览
张博,周奕阳,张敏峰,等.扶正祛邪方对肺癌患者无进展生存期的影响[J].上海中医药杂志,2024,58(12):114-118.

ZHANG Bo,ZHOU Yiyang,ZHANG Minfeng,et al.Effect of Fuzheng Quxie Formula on progression⁃free survival in lung cancer patients[J].Shanghai Journal of Traditional Chinese Medicine,2024,58(12):114-118.
张博,周奕阳,张敏峰,等.扶正祛邪方对肺癌患者无进展生存期的影响[J].上海中医药杂志,2024,58(12):114-118. DOI： 10.16305/j.1007-1334.2024.2404061.

ZHANG Bo,ZHOU Yiyang,ZHANG Minfeng,et al.Effect of Fuzheng Quxie Formula on progression⁃free survival in lung cancer patients[J].Shanghai Journal of Traditional Chinese Medicine,2024,58(12):114-118. DOI： 10.16305/j.1007-1334.2024.2404061.

摘要

目的

回顾性分析扶正祛邪方对肺癌患者无进展生存期（PFS）的影响，探讨影响肺癌预后的相关因素。

方法

收集肺癌患者的病历数据并进行随访，根据扶正祛邪方的使用情况分为治疗组（在常规治疗的基础上加用扶正祛邪方）、对照组（仅采用常规治疗），采用倾向性评分匹配（PSM），分析匹配前后两组患者的PFS并借助Kaplan-Meier法计算无进展生存率；用log-rank法进行单因素分析，然后采用多因素Cox回归分析，探讨影响肺癌患者PFS的相关因素。

结果

①本研究共收集1 134例肺癌患者的病历数据，PSM前对照组为373例、治疗组为761例，PSM后对照组、治疗组各208例。②PSM前后，治疗组平均PFS时间均较对照组延长［

=0.724，95%

（0.614～0.846），

0.001；

=0.5，95%

（0.387～0.646），

0.001］；PSM前后，治疗组I期患者的平均PFS时间均较对照组I期患者延长［

=0.203，95%

（0.138～0.298），

0.001；

=0.219，95%

（0.128～0.374），

0.001］。③单因素分析结果显示，性别、年龄、吸烟史、家族史、手术、化学疗法、分期、扶正祛邪方干预是影响肺癌患者PFS的相关因素（

0.05）；多因素回归分析结果显示，低龄［

=1.04，95%

（1.02～1.06），

0.001］、扶正祛邪方干预［

HR=

0.97，95%

（0.14～0.36），

0.001］是影响肺癌PFS的独立保护因素，吸烟［

=0.58，95%

（1.20～2.90），

=0.006］、分期［

=0.83，95%

（0.81～1.28），

0.001］是影响肺癌PFS的独立危险因素。④随访期间，两组患者均未见明显不良反应发生。

结论

扶正祛邪方是肺癌患者生存预后的保护性因素，有助于预防复发转移，延长肺癌患者的PFS，且对早期肺癌患者的影响更为显著，有良好的应用前景。

Abstract

Objective

To retrospectively analyze the effect of Fuzheng Quxie Formula （a decoction for strengthening the body's resistance and dispelling pathogenic factors） on the progression-free survival （PFS） in lung cancer patients and to explore the factors affecting the prognosis of lung cancer.

Methods

Clinical data from lung cancer patients were collected， and follow-up was conducted with them. Patients were divided into a treatment group （receiving the Fuzheng Quxie Formula in addition to conventional treatment） and a control group only （receiving conventional treatment） based on the use of the Fuzheng Quxie Formula. Propensity score matching （PSM） was used to compare PFS between the two groups before and after matching. Kaplan-Meier analysis was used to calculate PFS rates. Univariate analysis was conducted using the log-rank test. Multivariate Cox regression analysis was then used to identify factors affecting PFS in lung cancer patients.

Results

①A total of 1 134 lung cancer patients data were collected in this study， with 373 cases in the control group and 761 cases in the treatment group before PSM. After PSM， both the control and treatment groups had 208 cases each. ②The average PFS time in the treatment group was significantly longer than that in the control group before and after PSM ［

=0.724， 95%

（0.614-0.846），

0.001；

=0.5， 95%

（0.387-0.646），

0.001］. Specifically， stage Ⅰ patients in the treatment group had a longer average PFS time than those in the control group before and after PSM ［

=0.203， 95%

（0.138-0.298），

0.001；

=0.219， 95%

（0.128-0.374），

0.001］. ③Univariate analysis results showed that gender， age， smoking history， family history， surgery， chemotherapy， cancer staging， and the Fuzheng Quxie Formula intervention were significant related factors affecting PFS in lung cancer patients （

0.05）. Multivariate regression analysis results showed that younger age ［

=1.04， 95%

（1.02-1.06），

0.001］ and the Fuzheng Quxie Formula intervention ［

=0.97， 95%

（0.14-0.36），

0.001］ were independent protective factors affecting PFS in lung cancer patients， while smoking ［

=0.58， 95%

（

1.20-2.90），

=0.006］ and cancer staging ［

=0.83， 95%

（0.81-1.28），

0.001］ were independent risk factors affecting PFS in lung cancer patients. ④No significant adverse reactions were observed in either group during the follow-up period.

Conclusions

The Fuzheng Quxie Formula is a protective factor for the survival prognosis of lung cancer patients. It helps to prevent recurrence and metastasis， thereby prolonging PFS， particularly in early-stage lung cancer patients， and shows promising potential for clinical application.

关键词

肺癌扶正祛邪方无进展生存期中医药疗法生存分析回顾性研究

Keywords

lung cancerFuzheng Quxie Formulaprogression-free survivaltraditional Chinese medicine therapysurvival analysisretrospective study

references

HE Y T， LIANG D， LI D J， et al. Incidence and mortality of laryngeal cancer in China， 2015［J］. Chin J Cancer Res， 2020， 32（1）： 10-17.

CHANSKY K， DETTERBECK F C， NICHOLSON A G， et al. The IASLC Lung Cancer Staging Project：External Validation of the Revision of the TNM Stage Groupings in the Eighth Edition of the TNM Classification of Lung Cancer［J］. J Thorac Oncol， 2017， 12（7）： 1109-1121.

郑荣寿，孙可欣，张思维，等. 2015年中国恶性肿瘤流行情况分析［J］. 中华肿瘤杂志， 2019， 41（1）： 19-28.

ZHANG S F， CHEN W Q， WANG Y L， et al. Chinese herbal prescription Fu-Zheng-Qu-Xie Prevents recurrence and metastasis of postoperative early-stage lung adenocarcinoma：a prospective cohort study followed with potential mechanism exploration［J］. Oxid Med Cell Longev， 2021， 2021： 6673828.

中华人民共和国国家卫生健康委员会. 原发性肺癌诊疗指南（2022年版）［J］. 中国合理用药探索， 2022， 19（9）： 1-28.

LEITER A， VELUSWAMY R R， WISNIVESKY J P. The global burden of lung cancer： current status and future trends［J］. Nat Rev Clin Oncol， 2023， 20（9）： 624-639.

陈皖晴，张博，曹亚娟，等. 髓源抑制细胞介导肿瘤免疫微环境重塑及靶向治疗的研究进展［J］. 上海中医药杂志， 2019， 53（11）： 6.

刘芳芳，蔡雨晴，姜怡，等. 扶正方药治疗三线及以上晚期非小细胞肺癌临床疗效及对血清可溶性免疫检查点表达的影响［J］. 上海中医药杂志， 2024， 58（4）： 72-78.

刘素彤，李雁. 扶正祛邪方对肺癌患者外周血免疫指标的影响及与预后的相关性［J］. 吉林中医药， 2019， 39（2）： 219-222.

刘素彤，张素芳，骆莹滨，等. 扶正祛邪方提高肺癌患者无进展生存期回顾性队列研究［J］. 中医学报， 2019， 34（7）： 1497-1501.

郭鹏，骆莹滨，许荣忠，等. 扶正祛邪方辅助多西塞他联合顺铂化疗干预中晚期肺癌合并高脂血症的效果及机制［J］. 辽宁中医杂志， 2020， 47（12）： 136-139.

方志红，李雁，李天苗. 扶正祛邪方联合化疗治疗晚期非小细胞肺癌疗效分析［J］. 时珍国医国药， 2013， 24（10）： 2433-2434.

方志红，李雁，徐静，等. 扶正祛邪方联合化疗治疗45例晚期非小细胞肺癌临床观察［J］. 辽宁中医杂志， 2013， 40（12）： 2498-2500.

方志红，王艳春，李雁，等. 扶正祛邪方对肺癌A549细胞发生上皮间质转化的抑制作用研究［J］. 辽宁中医杂志， 2015， 42（4）： 207-209.

李赛凯，骆莹滨，吴建春，等. 益气扶正方对Lewis肺癌小鼠抑瘤作用的实验研究［J］. 中华中医药学刊， 2017， 35（3）： 569-572.

李雁，方志红. 扶正祛邪治则及其联合化疗对Lewis肺癌小鼠抑瘤作用［J］. 中华中医药学刊， 2011， 29（10）： 2176-2178.

Views

下载量

CSCD

CNKI被引量

Alert me when the article has been cited

提交

Tools

Publicity Resources

Effect of Fuzheng Quxie Formula on immune function and disease⁃free survival in postoperative patients with stage ⅠA micropapillary/solid‑dominant positive invasive lung adenocarcinoma

CiteSpace and VOSviewer⁃based analysis of current status and development trends in lung cancer metastasis research in China over past 20 years

Li Yan's experience in treating lung cancer with strengthening vital qi to eliminate pathogenic factor method

Clinical research on effects of Fuzheng Quxie Formula on preventing recurrence and metastasis in stage ⅠB⁃ⅡB non⁃small cell lung cancer and on humoral immune function

Exploring pathogenesis and treatment of autoimmune diseases from perspective of "transformation of Weiqi into Huaqi"

Related Author

MEI Na

WU Jianchun

JIANG Lei

LI Yan

LUO Yingbin

LUO Bin

CHU Xiaoge

LI Jiaxuan

Related Institution

Department of Oncology， Shanghai Municipal Hospital of Traditional Chinese Medicine Affiliated to Shanghai University of Traditional Chinese Medicine

Department of Thoracic Surgery， Shanghai Pulmonary Hospital

Center of Clinical Oncology， Shanghai Municipal Hospital of Traditional Chinese Medicine

Cancer Research Institute， Shanghai Municipal Hospital of Traditional Chinese Medicine

Department of Hematological Oncology， Shanghai Jing'an District Beizhan Hospital

⁰